Sewon Cellontech's Catifil Ankle Cartilage Injury Treatment Effect Published in International Academic Journal

[Asia Economy Reporter Hyungsoo Park] Sewon Cellontech announced on the 5th that a clinical paper proving the therapeutic effect of the tissue repair biomaterial 'Cartifil' on osteochondral lesions of the ankle joint was published in the SCI(E) international journal 'BMC Musculoskeletal Disorders.'

Cartifil is a tissue repair biomaterial made from bio-collagen raw materials used to support the placement of chondrocytes and bone marrow in areas of articular cartilage defects.

The paper reports the results of a 2-year multicenter randomized controlled trial (RCT) conducted on 60 patients suffering from osteochondral (bone and articular cartilage tissue) lesions in the talus (the ankle bone above the foot) of the ankle joint.

Professor Younggu Lee, the first author of the paper and an orthopedic surgeon at Soonchunhyang University Bucheon Hospital, evaluated the clinical research results, stating, "The clinical improvement effect and cartilage quality in the test group using Cartifil were significantly superior."

He further explained, "Histological analysis showed that in patients treated with Cartifil, Collagen Type II, a major component of cartilage tissue, was abundantly expressed in the osteochondral lesions of the ankle joint, indicating the formation of high-quality new cartilage."

Sewon Cellontech's Regenerative Medical System Innovation Center emphasized the significance of accumulating meaningful comparative clinical trial results targeting the ankle joint following the knee joint with Cartifil.

Through a multicenter randomized controlled trial involving many patients, long-term follow-up, and in-depth histological, clinical, and imaging evaluations, the study demonstrated the medical value and necessity of Cartifil for the ankle joint with reliability and scale.

Seodongsam Seo, director of Sewon Cellontech's Regenerative Medical System Innovation Center, said, "The clinical excellence of Cartifil using bio-collagen characterized by biocompatibility, safety, and tissue regeneration, as well as the clinical usefulness and convenience of improved microfracture surgery using Cartifil, will provide a treatment alternative for osteochondral lesions of the ankle joint."

Sewon Cellontech is currently promoting entry into the ASEAN market for Cartifil, which is in use for patient treatment, with Singapore as its base.